|Day Low/High||111.01 / 112.25|
|52 Wk Low/High||84.64 / 132.13|
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.
When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.
In this day and age, companies must be 'disruptors' or get left in the dust.
David Tepper's Appaloosa LP renews calls for changes at the top.
If we can advance without China then who the heck knows where we can go with it.
Pets can bring significant profits to companies that cater to this niche market.
Focus on individual stock picking, and take a look at small-caps, as earnings season continues.
The market can still go higher, but the time has come for the slope of price discovery to normalize a bit.
Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.
These themes are working despite the turmoil in Washington and slowing global growth.
So far 2019 is proving to be a year where things have a habit of working out right.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
This is the kind of reversal that happens in a bull market.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Whether this is the end of the slump is still up for debate, but the crash since October has been brutal and all bear markets end the same way.
A close below $105 for the drugmaker's shares would be bearish based on its charts.
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.